<DOC>
	<DOCNO>NCT01607372</DOCNO>
	<brief_summary>GSK2245035 highly selective Toll-like receptor 7 ( TLR7 ) agonist stimulate preferentially induction type I interferon . Intranasal ( i.n . ) administration GSK2245035 humans cause immune change upper airway milieu may alter bystander immune responsiveness aeroallergens contribute reduction allergic reactivity subject respiratory allergy . The purpose study examine safety pharmacodynamics ( PD ) repeat dose i.n . GSK2245035 subject respiratory allergy . The safety pharmacodynamic response four weekly administration escalate dos i.n . GSK2245035 investigate maximum tolerated dose establish . The study conduct patient symptomatic allergic rhinitis mild asthma . The overall duration study maximum approximately 122 day consider 90 day screen period , 22 day treatment period 10 day follow-up period .</brief_summary>
	<brief_title>A Study Investigate Safety Pharmacodynamics Repeat Intranasal Administration TLR7 Agonist GSK2245035 Subjects With Respiratory Allergies</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Good general health , determine responsible experienced physician , base medical evaluation , include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include investigator agree find unlikely introduce additional risk factor interfere study procedure . Males 18 62 year age inclusive . Male subject female partner childbearing potential must agree use one contraception method list protocol . This criterion must follow time first dose study medication four day last dosing . Females 18 62 year age inclusive , nonchildbearing potential , define premenopausal female document tubal ligation hysterectomy , postmenopausal , define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) great 40 MlU/ml estradiol le 40 pg/ml ( le 147 pmol/L ) confirmatory ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method protocol wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Body weight great equal 50 kilogram ( kg ) body mass index ( BMI ) within range 19 35 kg/meter square ( m^2 ) ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . Available complete require study measurement . Documented history Symptomatic perennial allergic rhinitis mild asthma drive house dust mite ( HDM ) 3 year , require regular use inhale steroid . Subjects symptomatic perennial allergic rhinitis mild asthma drive house dust mite ( HDM ) need positive skin allergy test ( wheal ≥ 3 millimeter [ mm ] ) RAST ( ≥ class 2 ) house dust mite allergen . ( However , allergen radio allergosorbent test [ RAST ] skin test omit subject provide clear evidence confirm physician analogous positive test within last 3 year ) . History immunological disorder disease ( include , limited , malignancy , cardiovascular , gastrointestinal , hepatic , renal , haematological , neurological , endocrine pulmonary disease ) opinion investigator GSK medical monitor may pose additional risk factor Nasal condition accord opinion investigator may affect outcome study , i.e . nasal septal perforation , nasal polyp , nasal malformation history frequent nosebleed . Respiratory tract infection within 4 week prior first dose . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive test HIV antibody A positive screening predose drug/alcohol screen History regular alcohol consumption within 6 month study define : average weekly intake great 14 drink male great 7 drink female . One drink equivalent 12 gram ( g ) alcohol : 12 ounce ( 360 millileter [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . Participation clinical trial receipt investigational product within 3 month prior first dose day . Exposure four new chemical entity within 6 month prior first dose day . History drug allergy , opinion investigator GSK medical monitor , contraindicate participation study . Donation blood blood product excess 500 mL within 56day period . History sensitivity heparin heparininduced thrombocytopenia Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History severe asthma Serious asthma exacerbation require hospital visit and/ treatment oral steroid high dos inhale steroid within 6 week prior screen History treatment allergenspecific immunotherapy Prebronchodilator FEV1 less equal 70 % predict screening Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dosing , unless opinion investigator GlaxoSmithKline ( GSK ) medical monitor medication interfere study procedure compromise subject safety . Paracetamol exception permit daily dos 4 g screen followup . During dose visit Paracetamol use , need , investigator allows . Subjects use steroid treatment allergic rhinitis and/or asthma may participate study remain free medication throughout study period start follow period time prior first dosing : Nasal steroid : 4 week ; Oral steroid : 12 week ; Inhaled steroid : 4 week Subjects use medication allergic rhinitis and/or asthma need basis may participate study abstain : Xanthines ( include theophylline , include caffeine ) , anticholinergic , cromoglycates , leukotriene antagonist , 5lipoxygenase inhibitor longacting inhaled betaagonists 1 week prior screen throughout study Na ; Nasal antihistamine : 48 hour prior dose ; Oral antihistamine : 76 hour prior dose ; Nasal decongestant : 24 hour prior dose ; Oral decongestant : 24 hour prior dose ; Short act inhaled betaagonists : 48 hour prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>62 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>TLR7 agonist , Respiratory Allergies , Allergic Rhinitis , Mild Allergic Asthma , Repeat Dose Safety , Reduction Allergic Reactivity</keyword>
</DOC>